SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 09/27/2024 at 15:35, 1 year 8 months ago

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
US FDA approves Dupixent as the first-ever biologic medicine for COPD, based on phase 3 studies showing significant reduction in exacerbations and improved lung function. Dupixent is now leading in new-to-brand prescriptions for FDA-approved indications

FDA Approval Dupixent COPD Treatment Biologic Medicine Phase 3 Studies
PRESS RELEASE

published on 09/27/2024 at 15:35, 1 year 8 months ago

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
La FDA approuve Dupixent comme premier médicament biologique pour la BPCO aux États-Unis, offrant un nouveau traitement aux patients inadéquatement contrôlés. Résultats positifs des études BOREAS et NOTUS

FDA Traitement Études BPCO Dupixent
BRIEF

published on 09/27/2024 at 13:05, 1 year 8 months ago

Dupixent Authorized in China as First Biologic Medicine for COPD Patients

China Approval COPD Dupixent Biologic Medicine
BRIEF

published on 09/27/2024 at 13:05, 1 year 8 months ago

Dupixent autorisé en Chine comme premier médicament biologique pour les patients atteints de BPCO

Chine MPoC Approbation Dupixent Médecine Biologique
PRESS RELEASE

published on 09/27/2024 at 13:00, 1 year 8 months ago

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for COPD patients, following landmark phase 3 studies. Approval crucial for addressing COPD burden in China

China COPD Dupixent Biologic Medicine Phase 3 Studies
PRESS RELEASE

published on 09/27/2024 at 13:00, 1 year 8 months ago

Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO
Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO, réduit les exacerbations et améliore la fonction respiratoire. Approbation suite à études de phase III

Traitement Chine Approbation BPCO Dupixent
BRIEF

published on 09/21/2024 at 00:41, 1 year 9 months ago

Approbation du Sarclisa aux États-Unis pour le traitement du myélome multiple

FDA Sanofi Myélome Multiple Sarclisa Traitement De Première Ligne
BRIEF

published on 09/21/2024 at 00:41, 1 year 9 months ago

Sarclisa Approved in the United States for the Treatment of Multiple Myeloma

FDA Sanofi Multiple Myeloma Sarclisa First Line Treatment
PRESS RELEASE

published on 09/21/2024 at 00:36, 1 year 9 months ago

Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)
La FDA approuve le Sarclisa aux États-Unis en association avec un traitement conventionnel pour les patients atteints de myélome multiple nouvellement diagnostiqué, non éligibles à une transplantation. Sanofi comble un vide thérapeutique important

FDA Traitement Sanofi Myélome Multiple Sarclisa
BRIEF

published on 09/20/2024 at 13:50, 1 year 9 months ago

Le CHMP recommande l'approbation du Dupixent pour les enfants de 12 mois et plus

Médicament Dupixent Enfants CHMP Œsophagite

Published on 06/25/2026 at 22:30, 5 minutes ago

Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 1 hour 3 minutes ago

BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 7 hours 5 minutes ago

Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/25/2026 at 15:00, 7 hours 35 minutes ago

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Published on 06/25/2026 at 14:30, 8 hours 5 minutes ago

Unusual Machines Expands Orlando Manufacturing Footprint to Support Battery Operations

View all ACCESSWIRE

Published on 06/25/2026 at 19:00, 3 hours 34 minutes ago

EQS-Adhoc: H&R GmbH & Co. KGaA resolves to prepare for the transition from the regulated market (Prime Standard) to the Scale segment of the Frankfurt Stock Exchange
Published on 06/25/2026 at 18:59, 3 hours 36 minutes ago

OHB Digital Connect completes upgrade of military ground stations
Published on 06/25/2026 at 18:40, 3 hours 55 minutes ago

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias
Published on 06/25/2026 at 18:30, 4 hours 5 minutes ago

Delisting of Northern Data AG Shares - Munich Stock Exchange Decides on the Timeline
Published on 06/25/2026 at 18:00, 4 hours 35 minutes ago

EUROPLASMA: Projet de cession des activités de défense : poursuite des discussions

View all EQS

Published on 06/25/2026 at 18:45, 3 hours 50 minutes ago

Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 4 hours 5 minutes ago

Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 4 hours 45 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 06/25/2026 at 17:50, 4 hours 45 minutes ago

DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 06/25/2026 at 15:58, 6 hours 37 minutes ago

260625 BENETEAU Transactions sur actions propres

View all LES ECHOS COMFI WIRE

News